Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TREM2MEDS

Financiado

Cerrado

Towards the clinical implementation of TREM2 Microglia Engineering for treating...

Towards the clinical implementation of TREM2 Microglia Engineering for treating DementiaS TREM2MEDS emerges from the ERC PoC 2022 project TREM2μENGINES (Grant agreement ID: 101069395), which validated the efficacy of a novel treatment for Alzheimer’s Disease (AD) and Nasu-Hakola Disease (NHD) in murine models. A releva... ver más

31/03/2027

UNIPD

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PADOVA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-05

HORIZON-EIC-2023-TRANSITIONOPEN-01: EIC Transition Open 2023 Scope:EIC Transition funds innovation activities that go beyond the experimental proof of principle...

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

UNIPD

1.73M€ | Lider

INSERM

268.18K€ | Participante

UNISMART

109.00K€ | Participante

IMG

499.42K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

iMIND iPS derived MIcroglia and Neuroinflammation in Dementia 269K€ Cerrado

PHAGO Inflammation and AD modulating microglia function focussing... 18M€ Cerrado

TREM2MICROENGINES TREM2 MICROglia ENGENEering for treating dementiaS (TREM2MIC... 150K€ Cerrado

ADAMtx ADAMtx Development of Alzheimer s immunotherapy by harnessi... 150K€ Cerrado

CELLPHASE_AD Genetics to understand cellular components of Alzheimer Dise... 2M€ Cerrado

PID2021-129053OB-I00 PLASTICIDAD DE MICROGLÍA EN DEMENCIA 169K€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2024-03-05
Fecha Fin: 2027-03-31

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PADOVA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto TREM2MEDS emerges from the ERC PoC 2022 project TREM2μENGINES (Grant agreement ID: 101069395), which validated the efficacy of a novel treatment for Alzheimer’s Disease (AD) and Nasu-Hakola Disease (NHD) in murine models. A relevant proportion of AD cases and all forms of NHD are caused by pathogenic mutations in the TREM2 gene, which lead to microglia dysfunction contributing to and/or causing the onset and manifestations of AD and NHD. TREM2MEDS approach involves the transplantation of hematopoietic stem/progenitor cells (HSPCs) engineered by lentiviral vectors (LVs) to express robust levels of the Triggering receptor expressed on myeloid cells 2 (TREM2) in their central nervous system (CNS) myeloid/microglial progeny. The engineered cells have shown the ability to reduce and prevent Aβ accumulation, mitigate neuroinflammation and restore physiological scavenging functions in the diseased CNS, benefiting AD and NHD in robust animal models. In TREM2MEDS, we will exploit these findings for transition of the approach from TRL 4 to TRL 5/6 by generating IMPD-enabling data and packages that will allow launching, at project completion, a first-in-human Phase I clinical trial of TREM2-HSPC gene therapy in AD & NHD patients carrying TREM2 hypofunctional variants. The restoration of TREM2 function in microglia, by intervening on key mechanisms contributing to neurodegeneration, has the potential to overcome the limited efficacy of current treatments for AD, which only exert symptomatic but not curative effects. Through this work we will thus bring to clinical testing an approach intended to become the benchmark in the treatment of AD and NHD, and possibly other dementias.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores